{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T11:34:35Z","timestamp":1771068875879,"version":"3.50.1"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,3,30]],"date-time":"2013-03-30T00:00:00Z","timestamp":1364601600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. of Cardiovasc. Trans. Res."],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s12265-013-9458-z","type":"journal-article","created":{"date-parts":[[2013,3,29]],"date-time":"2013-03-29T15:50:01Z","timestamp":1364572201000},"page":"316-328","source":"Crossref","is-referenced-by-count":31,"title":["Platelet Function Testing and Tailored Antiplatelet Therapy"],"prefix":"10.1007","volume":"6","author":[{"given":"Paul W. A.","family":"Janssen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jurri\u00ebn M.","family":"ten Berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,3,30]]},"reference":[{"key":"9458_CR1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jacc.2011.08.007","volume":"58","author":"GN Levine","year":"2011","unstructured":"Levine, G. N., Bates, E. R., Blankenship, J. C., Bailey, S. R., Bittl, J. A., et al. (2011). 2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Journal of the American College of Cardiology, 58, 44\u2013122.","journal-title":"Journal of the American College of Cardiology"},{"key":"9458_CR2","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/j.jacc.2012.11.019","volume":"61","author":"PT O\u2019Gara","year":"2013","unstructured":"O\u2019Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Jr., Chung, M. K., et al. (2013). 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 61, e78\u2013e140.","journal-title":"Journal of the American College of Cardiology"},{"key":"9458_CR3","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jacc.2012.06.004","volume":"60","author":"H Jneid","year":"2012","unstructured":"Jneid, H., Anderson, J. L., Wright, R. S., Adams, C. D., Bridges, C. R., et al. (2012). 2012 ACCF\/AHA focused update of the guideline for the management of patients with unstable angina\/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 60, 645\u2013681.","journal-title":"Journal of the American College of Cardiology"},{"key":"9458_CR4","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","volume":"33","author":"PG Steg","year":"2012","unstructured":"Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg, P. G., James, S. K., Atar, D., Badano, L. P., et al. (2012). ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 33, 2569\u20132619.","journal-title":"European Heart Journal"},{"key":"9458_CR5","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","volume":"32","author":"CW Hamm","year":"2011","unstructured":"Hamm, C. W., Bassand, J. P., Agewall, S., Bax, J., Boersma, E., et al. (2011). ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal, 32, 2999\u20133054.","journal-title":"European Heart Journal"},{"key":"9458_CR6","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","volume":"345","author":"S Yusuf","year":"2001","unstructured":"Yusuf, S., Zhao, F., Mehta, S. R., Chrolavicius, S., Tognoni, G., et al. (2001). Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. The New England Journal of Medicine, 345, 494\u2013502.","journal-title":"The New England Journal of Medicine"},{"key":"9458_CR7","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","volume":"358","author":"SR Mehta","year":"2001","unstructured":"Mehta, S. R., Yusuf, S., Peters, R. J., Bertrand, M. E., Lewis, B. S., et al. (2001). Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet, 358, 527\u2013533.","journal-title":"Lancet"},{"key":"9458_CR8","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","volume":"288","author":"SR Steinhubl","year":"2002","unstructured":"Steinhubl, S. R., Berger, P. B., Mann, J. T., 3rd, Fry, E. T., DeLago, A., et al. (2002). Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. Journal of the American Medical Association, 288, 2411\u20132420.","journal-title":"Journal of the American Medical Association"},{"key":"9458_CR9","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","volume":"366","author":"ZM Chen","year":"2005","unstructured":"Chen, Z. M., Jiang, L. X., Chen, Y. P., Xie, J. X., Pan, H. C., et al. (2005). Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet, 366, 1607\u20131621.","journal-title":"Lancet"},{"key":"9458_CR10","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","volume":"352","author":"MS Sabatine","year":"2005","unstructured":"Sabatine, M. S., Cannon, C. P., Gibson, C. M., Lopez-Sendon, J. L., Montalescot, G., et al. (2005). Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. The New England Journal of Medicine, 352, 1179\u20131189.","journal-title":"The New England Journal of Medicine"},{"key":"9458_CR11","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1001\/jama.294.10.1224","volume":"294","author":"MS Sabatine","year":"2005","unstructured":"Sabatine, M. S., Cannon, C. P., Gibson, C. M., Lopez-Sendon, J. L., Montalescot, G., et al. (2005). Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. Journal of the American Medical Association, 294, 1224\u20131232.","journal-title":"Journal of the American Medical Association"},{"key":"9458_CR12","doi-asserted-by":"crossref","unstructured":"Herbert, J. M., & Savi, P. (2003). P2Y12, a new platelet ADP receptor, target of clopidogrel. Seminars in Vascular Medicine, 3, 113\u2013122.","DOI":"10.1055\/s-2003-40669"},{"key":"9458_CR13","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","volume":"56","author":"L Bonello","year":"2010","unstructured":"Bonello, L., Tantry, U. S., Marcucci, R., Blindt, R., Angiolillo, D. J., et al. (2010). Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. Journal of the American College of Cardiology, 56, 919\u2013933.","journal-title":"Journal of the American College of Cardiology"},{"key":"9458_CR14","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/j.1538-7836.2010.03809.x","volume":"8","author":"C Combescure","year":"2010","unstructured":"Combescure, C., Fontana, P., Mallouk, N., Berdague, P., Labruyere, C., et al. (2010). Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis. Journal of Thrombosis and Haemostasis, 8, 923\u2013933.","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"9458_CR15","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.jacc.2011.06.059","volume":"58","author":"SS Brar","year":"2011","unstructured":"Brar, S. S., ten Berg, J., Marcucci, R., Price, M. J., Valgimigli, M., et al. (2011). Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. Journal of the American College of Cardiology, 58, 1945\u20131954.","journal-title":"Journal of the American College of Cardiology"},{"key":"9458_CR16","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1161\/01.CIR.0000160869.75810.98","volume":"111","author":"W Hochholzer","year":"2005","unstructured":"Hochholzer, W., Trenk, D., Frundi, D., Blanke, P., Fischer, B., et al. (2005). Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation, 111, 2560\u20132564.","journal-title":"Circulation"},{"key":"9458_CR17","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1161\/CIRCULATIONAHA.112.117283","volume":"127","author":"T Grosser","year":"2013","unstructured":"Grosser, T., Fries, S., Lawson, J. A., Kapoor, S. C., Grant, G. R., & Fitzgerald, G. A. (2013). Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation, 127, 377\u2013385.","journal-title":"Circulation"},{"key":"9458_CR18","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1001\/jama.2010.181","volume":"303","author":"NJ Breet","year":"2010","unstructured":"Breet, N. J., van Werkum, J. W., Bouman, H. J., Kelder, J. C., Ruven, H. J., et al. (2010). Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. Journal of the American Medical Association, 303, 754\u2013762.","journal-title":"Journal of the American Medical Association"},{"key":"9458_CR19","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1136\/hrt.2010.220509","volume":"97","author":"HJ Bouman","year":"2011","unstructured":"Bouman, H. J., Harmsze, A. M., van Werkum, J. W., Breet, N. J., Bergmeijer, T. O., et al. (2011). Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting. Heart, 97, 1239\u20131244.","journal-title":"Heart"},{"key":"9458_CR20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.recesp.2011.09.024","volume":"65","author":"TO Bergmeijer","year":"2012","unstructured":"Bergmeijer, T. O., & ten Berg, J. M. (2012). Value of CYP2C19 *2 and *17 genotyping in clinical practice. promising but not ready yet. Revista Espa\u00f1ola de Cardiolog\u00eda, 65, 205\u2013207 (Engl. Ed).","journal-title":"Revista Espa\u00f1ola de Cardiolog\u00eda"},{"key":"9458_CR21","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1001\/jama.2011.1703","volume":"306","author":"JL Mega","year":"2011","unstructured":"Mega, J. L., Hochholzer, W., Frelinger, A. L., 3rd, Kluk, M. J., Angiolillo, D. J., et al. (2011). Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. Journal of the American Medical Association, 306, 2221\u20132228.","journal-title":"Journal of the American Medical Association"},{"key":"9458_CR22","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/tpj.2010.21","volume":"11","author":"F Sofi","year":"2011","unstructured":"Sofi, F., Giusti, B., Marcucci, R., Gori, A. M., Abbate, R., & Gensini, G. F. (2011). Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. The Pharmacogenomics Journal, 11, 199\u2013206.","journal-title":"The Pharmacogenomics Journal"},{"key":"9458_CR23","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.clpt.2005.10.002","volume":"79","author":"SC Sim","year":"2006","unstructured":"Sim, S. C., Risinger, C., Dahl, M. L., Aklillu, E., Christensen, M., et al. (2006). A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clinical Pharmacology and Therapeutics, 79, 103\u2013113.","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"9458_CR24","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/FPC.0b013e32834ff6e3","volume":"22","author":"AM Harmsze","year":"2012","unstructured":"Harmsze, A. M., van Werkum, J. W., Hackeng, C. M., Ruven, H. J., Kelder, J. C., et al. (2012). The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting. Pharmacogenetics and Genomics, 22, 169\u2013175.","journal-title":"Pharmacogenetics and Genomics"},{"key":"9458_CR25","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.2337\/diabetes.54.8.2430","volume":"54","author":"DJ Angiolillo","year":"2005","unstructured":"Angiolillo, D. J., Fernandez-Ortiz, A., Bernardo, E., Ramirez, C., Sabate, M., et al. (2005). Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes, 54, 2430\u20132435.","journal-title":"Diabetes"},{"key":"9458_CR26","first-page":"169","volume":"16","author":"DJ Angiolillo","year":"2004","unstructured":"Angiolillo, D. J., Fernandez-Ortiz, A., Bernardo, E., Barrera Ramirez, C., Sabate, M., et al. (2004). Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? The Journal of Invasive Cardiology, 16, 169\u2013174.","journal-title":"The Journal of Invasive Cardiology"},{"key":"9458_CR27","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.thromres.2008.01.021","volume":"122","author":"AA Heestermans","year":"2008","unstructured":"Heestermans, A. A., van Werkum, J. W., Taubert, D., Seesing, T. H., von Beckerath, N., et al. (2008). Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thrombosis Research, 122, 776\u2013781.","journal-title":"Thrombosis Research"},{"key":"9458_CR28","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/eurheartj\/ehr407","volume":"33","author":"J Silvain","year":"2012","unstructured":"Silvain, J., Cayla, G., Hulot, J. S., Finzi, J., Kerneis, M., et al. (2012). High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study. European Heart Journal, 33, 1241\u20131249.","journal-title":"European Heart Journal"},{"key":"9458_CR29","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1345\/aph.1P425","volume":"45","author":"AM Harmsze","year":"2011","unstructured":"Harmsze, A. M., van Werkum, J. W., Taubert, D., Hackeng, C. M., & Deneer, V. H. (2011). Esomeprazole but not pantoprazole is associated with lower plasma concentrations of clopidogrel\u2019s active metabolite. The Annals of Pharmacotherapy, 45, 542\u2013543.","journal-title":"The Annals of Pharmacotherapy"},{"key":"9458_CR30","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1160\/TH09-08-0516","volume":"103","author":"AM Harmsze","year":"2010","unstructured":"Harmsze, A. M., Robijns, K., van Werkum, J. W., Breet, N. J., Hackeng, C. M., et al. (2010). The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. Thrombosis and Haemostasis, 103, 920\u2013925.","journal-title":"Thrombosis and Haemostasis"},{"key":"9458_CR31","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2217\/bmm.11.5","volume":"5","author":"JA Jakubowski","year":"2011","unstructured":"Jakubowski, J. A. (2011). Beyond platelet functional testing: value in the aggregate. Biomarkers in Medicine, 5, 5\u20138.","journal-title":"Biomarkers in Medicine"},{"key":"9458_CR32","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1161\/CIRCULATIONAHA.107.740324","volume":"116","author":"SD Wiviott","year":"2007","unstructured":"Wiviott, S. D., Trenk, D., Frelinger, A. L., O\u2019Donoghue, M., Neumann, F. J., et al. (2007). Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation\u2013thrombolysis in myocardial infarction 44 trial. Circulation, 116, 2923\u20132932.","journal-title":"Circulation"},{"key":"9458_CR33","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/eurheartj\/ehm545","volume":"29","author":"L Wallentin","year":"2008","unstructured":"Wallentin, L., Varenhorst, C., James, S., Erlinge, D., Braun, O. O., et al. (2008). Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. European Heart Journal, 29, 21\u201330.","journal-title":"European Heart Journal"},{"key":"9458_CR34","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., et al. (2007). Prasugrel versus clopidogrel in patients with acute coronary syndromes. The New England Journal of Medicine, 357, 2001\u20132015.","journal-title":"The New England Journal of Medicine"},{"key":"9458_CR35","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1161\/CIRCULATIONAHA.109.851949","volume":"119","author":"JL Mega","year":"2009","unstructured":"Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., et al. (2009). Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation, 119, 2553\u20132560.","journal-title":"Circulation"},{"key":"9458_CR36","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1111\/j.1538-7836.2012.04875.x","volume":"10","author":"L Bonello","year":"2012","unstructured":"Bonello, L., Mancini, J., Pansieri, M., Maillard, L., Rossi, P., et al. (2012). Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel. Journal of Thrombosis and Haemostasis, 10, 1999\u20132005.","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"9458_CR37","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","volume":"120","author":"PA Gurbel","year":"2009","unstructured":"Gurbel, P. A., Bliden, K. P., Butler, K., Tantry, U. S., Gesheff, T., et al. (2009). Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET\/OFFSET study. Circulation, 120, 2577\u20132585.","journal-title":"Circulation"},{"key":"9458_CR38","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1161\/CIRCULATIONAHA.109.919456","volume":"121","author":"PA Gurbel","year":"2010","unstructured":"Gurbel, P. A., Bliden, K. P., Butler, K., Antonino, M. J., Wei, C., et al. (2010). Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation, 121, 1188\u20131199.","journal-title":"Circulation"},{"key":"9458_CR39","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1161\/CIRCGENETICS.110.958561","volume":"3","author":"US Tantry","year":"2010","unstructured":"Tantry, U. S., Bliden, K. P., Wei, C., Storey, R. F., Armstrong, M., et al. (2010). First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET\/OFFSET and RESPOND genotype studies. Circulation. Cardiovascular Genetics, 3, 556\u2013566.","journal-title":"Circulation. Cardiovascular Genetics"},{"key":"9458_CR40","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1067\/mhj.2002.121734","volume":"143","author":"GL Wheeler","year":"2002","unstructured":"Wheeler, G. L., Braden, G. A., Steinhubl, S. R., Kereiakes, D. J., Kottke-Marchant, K., et al. (2002). The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy. American Heart Journal, 143, 602\u2013611.","journal-title":"American Heart Journal"},{"key":"9458_CR41","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1111\/j.1538-7836.2006.02187.x","volume":"4","author":"JW Werkum van","year":"2006","unstructured":"van Werkum, J. W., van der Stelt, C. A., Seesing, T. H., Hackeng, C. M., & ten Berg, J. M. (2006). A head-to-head comparison between the VerifyNow P2Y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary intervention. Journal of Thrombosis and Haemostasis, 4, 2516\u20132518.","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"9458_CR42","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1160\/TH06-01-0046","volume":"95","author":"N Beckerath von","year":"2006","unstructured":"von Beckerath, N., Pogatsa-Murray, G., Wieczorek, A., Sibbing, D., Schomig, A., & Kastrati, A. (2006). Correlation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsiveness. Thrombosis and Haemostasis, 95, 910\u2013911.","journal-title":"Thrombosis and Haemostasis"},{"key":"9458_CR43","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1160\/TH07-09-0575","volume":"99","author":"JA Jakubowski","year":"2008","unstructured":"Jakubowski, J. A., Payne, C. D., Li, Y. G., Brandt, J. T., Small, D. S., et al. (2008). The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration. Thrombosis and Haemostasis, 99, 409\u2013415.","journal-title":"Thrombosis and Haemostasis"},{"key":"9458_CR44","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1160\/TH07-07-0478","volume":"99","author":"D Sibbing","year":"2008","unstructured":"Sibbing, D., Braun, S., Jawansky, S., Vogt, W., Mehilli, J., et al. (2008). Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thrombosis and Haemostasis, 99, 121\u2013126.","journal-title":"Thrombosis and Haemostasis"},{"key":"9458_CR45","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1172\/JCI7569","volume":"105","author":"S Kulkarni","year":"2000","unstructured":"Kulkarni, S., Dopheide, S. M., Yap, C. L., Ravanat, C., Freund, M., et al. (2000). A revised model of platelet aggregation. The Journal of Clinical Investigation, 105, 783\u2013791.","journal-title":"The Journal of Clinical Investigation"},{"key":"9458_CR46","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1373\/clinchem.2004.047050","volume":"51","author":"J Geiger","year":"2005","unstructured":"Geiger, J., Teichmann, L., Grossmann, R., Aktas, B., Steigerwald, U., et al. (2005). Monitoring of clopidogrel action: comparison of methods. Clinical Chemistry, 51, 957\u2013965.","journal-title":"Clinical Chemistry"},{"key":"9458_CR47","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1538-7836.2004.01063.x","volume":"3","author":"B Aleil","year":"2005","unstructured":"Aleil, B., Ravanat, C., Cazenave, J. P., Rochoux, G., Heitz, A., & Gachet, C. (2005). Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. Journal of Thrombosis and Haemostasis, 3, 85\u201392.","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"9458_CR48","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1080\/09537100802351065","volume":"19","author":"PA Gurbel","year":"2008","unstructured":"Gurbel, P. A., Antonino, M. J., Bliden, K. P., Dichiara, J., Suarez, T. A., et al. (2008). Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target. Platelets, 19, 595\u2013604.","journal-title":"Platelets"},{"key":"9458_CR49","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.amjcard.2009.06.007","volume":"104","author":"T Cuisset","year":"2009","unstructured":"Cuisset, T., Frere, C., Quilici, J., Gaborit, B., Castelli, C., et al. (2009). Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients. The American Journal of Cardiology, 104, 1078\u20131082.","journal-title":"The American Journal of Cardiology"},{"key":"9458_CR50","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1160\/TH07-04-0296","volume":"98","author":"C Frere","year":"2007","unstructured":"Frere, C., Cuisset, T., Quilici, J., Camoin, L., Carvajal, J., et al. (2007). ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thrombosis and Haemostasis, 98, 838\u2013843.","journal-title":"Thrombosis and Haemostasis"},{"key":"9458_CR51","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.jacc.2010.03.103","volume":"56","author":"G Campo","year":"2010","unstructured":"Campo, G., Fileti, L., de Cesare, N., Meliga, E., Furgieri, A., et al. (2010). Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T\/2R (Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and\/or Resistance to Clopidogrel) trial substudy. Journal of the American College of Cardiology, 56, 1447\u20131455.","journal-title":"Journal of the American College of Cardiology"},{"key":"9458_CR52","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1093\/eurheartj\/ehn046","volume":"29","author":"MJ Price","year":"2008","unstructured":"Price, M. J., Endemann, S., Gollapudi, R. R., Valencia, R., Stinis, C. T., et al. (2008). Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. European Heart Journal, 29, 992\u20131000.","journal-title":"European Heart Journal"},{"key":"9458_CR53","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jcin.2012.01.009","volume":"5","author":"F Mangiacapra","year":"2012","unstructured":"Mangiacapra, F., Patti, G., Barbato, E., Peace, A. J., Ricottini, E., et al. (2012). A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet Therapy for Reduction of Myocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study. JACC. Cardiovascular Interventions, 5, 281\u2013289.","journal-title":"JACC. Cardiovascular Interventions"},{"key":"9458_CR54","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jacc.2008.06.038","volume":"52","author":"G Patti","year":"2008","unstructured":"Patti, G., Nusca, A., Mangiacapra, F., Gatto, L., D\u2019Ambrosio, A., & Di Sciascio, G. (2008). Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet Therapy for Reduction of Myocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. Journal of the American College of Cardiology, 52, 1128\u20131133.","journal-title":"Journal of the American College of Cardiology"},{"key":"9458_CR55","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1161\/CIRCULATIONAHA.108.812636","volume":"119","author":"R Marcucci","year":"2009","unstructured":"Marcucci, R., Gori, A. M., Paniccia, R., Giusti, B., Valente, S., et al. (2009). Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation, 119, 237\u2013242.","journal-title":"Circulation"},{"key":"9458_CR56","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jacc.2010.08.631","volume":"57","author":"JW Suh","year":"2011","unstructured":"Suh, J. W., Lee, S. P., Park, K. W., Lee, H. Y., Kang, H. J., et al. (2011). Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of cilostazol-based triple antiplatelet therapy on ischemic complication after drug-eluting stent implantation) trial. Journal of the American College of Cardiology, 57, 280\u2013289.","journal-title":"Journal of the American College of Cardiology"},{"key":"9458_CR57","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jacc.2008.11.030","volume":"53","author":"D Sibbing","year":"2009","unstructured":"Sibbing, D., Braun, S., Morath, T., Mehilli, J., Vogt, W., et al. (2009). Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. Journal of the American College of Cardiology, 53, 849\u2013856.","journal-title":"Journal of the American College of Cardiology"},{"key":"9458_CR58","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1160\/TH07-05-0324","volume":"98","author":"R Blindt","year":"2007","unstructured":"Blindt, R., Stellbrink, K., de Taeye, A., Muller, R., Kiefer, P., et al. (2007). The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thrombosis and Haemostasis, 98, 1329\u20131334.","journal-title":"Thrombosis and Haemostasis"},{"key":"9458_CR59","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1111\/j.1538-7836.2007.02609.x","volume":"5","author":"L Bonello","year":"2007","unstructured":"Bonello, L., Paganelli, F., Arpin-Bornet, M., Auquier, P., Sampol, J., et al. (2007). Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. Journal of Thrombosis and Haemostasis, 5, 1630\u20131636.","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"9458_CR60","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1016\/j.jacc.2010.12.047","volume":"57","author":"G Campo","year":"2011","unstructured":"Campo, G., Parrinello, G., Ferraresi, P., Lunghi, B., Tebaldi, M., et al. (2011). Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. Journal of the American College of Cardiology, 57, 2474\u20132483.","journal-title":"Journal of the American College of Cardiology"},{"key":"9458_CR61","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1001\/jama.2011.1332","volume":"306","author":"G Parodi","year":"2011","unstructured":"Parodi, G., Marcucci, R., Valenti, R., Gori, A. M., Migliorini, A., et al. (2011). High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. Journal of the American Medical Association, 306, 1215\u20131223.","journal-title":"Journal of the American Medical Association"},{"key":"9458_CR62","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1161\/CIRCULATIONAHA.111.029165","volume":"124","author":"MJ Price","year":"2011","unstructured":"Price, M. J., Angiolillo, D. J., Teirstein, P. S., Lillie, E., Manoukian, S. V., et al. (2011). Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the gauging responsiveness with a VerifyNow P2Y12 assay: impact on thrombosis and safety (GRAVITAS) trial. Circulation, 124, 1132\u20131137.","journal-title":"Circulation"},{"key":"9458_CR63","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jacc.2012.02.044","volume":"60","author":"D Sibbing","year":"2012","unstructured":"Sibbing, D., Bernlochner, I., Schulz, S., Massberg, S., Schomig, A., et al. (2012). Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy. Journal of the American College of Cardiology, 60, 369\u2013377.","journal-title":"Journal of the American College of Cardiology"},{"key":"9458_CR64","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jacc.2010.03.048","volume":"56","author":"D Sibbing","year":"2010","unstructured":"Sibbing, D., Steinhubl, S. R., Schulz, S., Schomig, A., & Kastrati, A. (2010). Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window. Journal of the American College of Cardiology, 56, 317\u2013318.","journal-title":"Journal of the American College of Cardiology"},{"key":"9458_CR65","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/eurheartj\/ehp434","volume":"31","author":"V Serebruany","year":"2010","unstructured":"Serebruany, V., Rao, S. V., Silva, M. A., Donovan, J. L., Kannan, A. O., et al. (2010). Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. European Heart Journal, 31, 227\u2013235.","journal-title":"European Heart Journal"},{"key":"9458_CR66","doi-asserted-by":"crossref","first-page":"325","DOI":"10.4244\/51","volume":"5","author":"T Cuisset","year":"2009","unstructured":"Cuisset, T., Cayla, G., Frere, C., Quilici, J., Poyet, R., et al. (2009). Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? EuroIntervention, 5, 325\u2013329.","journal-title":"EuroIntervention"},{"key":"9458_CR67","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1538-7836.2009.03709.x","volume":"8","author":"D Sibbing","year":"2010","unstructured":"Sibbing, D., Schulz, S., Braun, S., Morath, T., Stegherr, J., et al. (2010). Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. Journal of Thrombosis and Haemostasis, 8, 250\u2013256.","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"9458_CR68","doi-asserted-by":"crossref","unstructured":"Grosdidier C, Quilici J, Loosveld M, Camoin L, Moro PJ, et al. 2013. Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications. American Journal of Cardiology. doi: 10.1016\/j.amjcard.2012.12.013","DOI":"10.1016\/j.amjcard.2012.12.013"},{"key":"9458_CR69","unstructured":"Cardiovascular Research Foundation. 2012. Low responsiveness to clopidogrel predicts stent thrombosis, heart attack; but is not directly linked to death [press release]."},{"key":"9458_CR70","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1161\/CIRCULATIONAHA.106.667741","volume":"115","author":"DJ Angiolillo","year":"2007","unstructured":"Angiolillo, D. J., Shoemaker, S. B., Desai, B., Yuan, H., Charlton, R. K., et al. (2007). Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation, 115, 708\u2013716.","journal-title":"Circulation"},{"key":"9458_CR71","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1093\/eurheartj\/ehl489","volume":"28","author":"N Beckerath von","year":"2007","unstructured":"von Beckerath, N., Kastrati, A., Wieczorek, A., Pogatsa-Murray, G., Sibbing, D., et al. (2007). A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75\u00a0mg of clopidogrel for 30\u00a0days. European Heart Journal, 28, 1814\u20131819.","journal-title":"European Heart Journal"},{"key":"9458_CR72","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.amjcard.2007.09.087","volume":"101","author":"DJ Angiolillo","year":"2008","unstructured":"Angiolillo, D. J., Costa, M. A., Shoemaker, S. B., Desai, B., Bernardo, E., et al. (2008). Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment. The American Journal of Cardiology, 101, 440\u2013445.","journal-title":"The American Journal of Cardiology"},{"key":"9458_CR73","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.amjcard.2008.04.028","volume":"102","author":"S Matetzky","year":"2008","unstructured":"Matetzky, S., Fefer, P., Shenkman, B., Varon, D., Savion, N., & Hod, H. (2008). Effectiveness of reloading to overcome clopidogrel nonresponsiveness in patients with acute myocardial infarction. The American Journal of Cardiology, 102, 524\u2013529.","journal-title":"The American Journal of Cardiology"},{"key":"9458_CR74","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jcin.2008.09.004","volume":"1","author":"B Aleil","year":"2008","unstructured":"Aleil, B., Jacquemin, L., De Poli, F., Zaehringer, M., Collet, J. P., et al. (2008). Clopidogrel 150\u00a0mg\/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study. JACC. Cardiovascular Interventions, 1, 631\u2013638.","journal-title":"JACC. Cardiovascular Interventions"},{"key":"9458_CR75","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.jacc.2008.12.025","volume":"53","author":"YH Jeong","year":"2009","unstructured":"Jeong, Y. H., Lee, S. W., Choi, B. R., Kim, I. S., Seo, M. K., et al. (2009). Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients with Clopidogrel Resistance) randomized study. Journal of the American College of Cardiology, 53, 1101\u20131109.","journal-title":"Journal of the American College of Cardiology"},{"key":"9458_CR76","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jcin.2008.08.018","volume":"1","author":"T Cuisset","year":"2008","unstructured":"Cuisset, T., Frere, C., Quilici, J., Morange, P. E., Mouret, J. P., et al. (2008). Glycoprotein IIb\/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. JACC. Cardiovascular Interventions, 1, 649\u2013653.","journal-title":"JACC. Cardiovascular Interventions"},{"key":"9458_CR77","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.jacc.2007.12.044","volume":"51","author":"L Bonello","year":"2008","unstructured":"Bonello, L., Camoin-Jau, L., Arques, S., Boyer, C., Panagides, D., et al. (2008). Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. Journal of the American College of Cardiology, 51, 1404\u20131411.","journal-title":"Journal of the American College of Cardiology"},{"key":"9458_CR78","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.amjcard.2008.08.048","volume":"103","author":"L Bonello","year":"2009","unstructured":"Bonello, L., Camoin-Jau, L., Armero, S., Com, O., Arques, S., et al. (2009). Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. The American Journal of Cardiology, 103, 5\u201310.","journal-title":"The American Journal of Cardiology"},{"key":"9458_CR79","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1161\/CIRCULATIONAHA.108.833236","volume":"119","author":"M Valgimigli","year":"2009","unstructured":"Valgimigli, M., Campo, G., de Cesare, N., Meliga, E., Vranckx, P., et al. (2009). Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized tailoring treatment with tirofiban in patients showing resistance to aspirin and\/or resistance to clopidogrel study. Circulation, 119, 3215\u20133222.","journal-title":"Circulation"},{"key":"9458_CR80","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.2011.290","volume":"305","author":"MJ Price","year":"2011","unstructured":"Price, M. J., Berger, P. B., Teirstein, P. S., Tanguay, J. F., Angiolillo, D. J., et al. (2011). Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. Journal of the American Medical Association, 305, 1097\u20131105.","journal-title":"Journal of the American Medical Association"},{"key":"9458_CR81","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/clc.20884","volume":"34","author":"X Wang","year":"2011","unstructured":"Wang, X., Zhang, D., Zhuang, S., & Lai, Y. (2011). Modifying clopidogrel maintenance doses according to vasodilator-stimulated phosphoprotein phosphorylation index improves clinical outcome in patients with clopidogrel resistance. Clinical Cardiology, 34, 332\u2013338.","journal-title":"Clinical Cardiology"},{"key":"9458_CR82","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","volume":"59","author":"D Trenk","year":"2012","unstructured":"Trenk, D., Stone, G. W., Gawaz, M., Kastrati, A., Angiolillo, D. J., et al. (2012). A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity in Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy with Prasugrel) study. Journal of the American College of Cardiology, 59, 2159\u20132164.","journal-title":"Journal of the American College of Cardiology"},{"key":"9458_CR83","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","volume":"367","author":"JP Collet","year":"2012","unstructured":"Collet, J. P., Cuisset, T., Range, G., Cayla, G., Elhadad, S., et al. (2012). Bedside monitoring to adjust antiplatelet therapy for coronary stenting. The New England Journal of Medicine, 367, 2100\u20132109.","journal-title":"The New England Journal of Medicine"},{"key":"9458_CR84","doi-asserted-by":"crossref","first-page":"617098","DOI":"10.1155\/2012\/617098","volume":"2012","author":"TC Godschalk","year":"2012","unstructured":"Godschalk, T. C., Hackeng, C. M., & Ten Berg, J. M. (2012). Towards personalized medicine based on platelet function testing for stent thrombosis patients. Thrombosis, 2012, 617098.","journal-title":"Thrombosis"}],"container-title":["Journal of Cardiovascular Translational Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-013-9458-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12265-013-9458-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-013-9458-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T18:56:03Z","timestamp":1688151363000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12265-013-9458-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,30]]},"references-count":84,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["9458"],"URL":"https:\/\/doi.org\/10.1007\/s12265-013-9458-z","relation":{},"ISSN":["1937-5387","1937-5395"],"issn-type":[{"value":"1937-5387","type":"print"},{"value":"1937-5395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,30]]}}}